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The rising burden of dementia is a global concern, and there is a need to study its causes, natural
history and outcomes. The Secure Anonymised Information Linkage (SAIL) Databank contains
anonymised, routinely-collected healthcare data for the population of Wales, UK. It has potential to
be a valuable resource for dementia research owing to its size, long follow-up time and prospective
collection of data during clinical care.
Objectives
We aimed to apply reproducible methods to create the SAIL dementia e-cohort (SAIL-DeC). We
created SAIL-DeC with a view to maximising its utility for a broad range of research questions whilst
minimising duplication of effort for researchers.
Methods
SAIL contains individual-level, linked primary care, hospital admission, mortality and demographic
data. Data are currently available until 2018 and future updates will extend participant follow-up
time. We included participants who were born between 1st January 1900 and 1st January 1958
and for whom primary care data were available. We applied algorithms consisting of International
Classification of Diseases (versions 9 and 10) and Read (version 2) codes to identify participants
with and without all-cause dementia and dementia subtypes. We also created derived variables for
comorbidities and risk factors.
Results
From 4.4 million unique participants in SAIL, 1.2 million met the cohort inclusion criteria, resulting
in 18.8 million person-years of follow-up. Of these, 129,650 (10%) developed all-cause dementia,
with 77,978 (60%) having dementia subtype codes. Alzheimer’s disease was the most common
subtype diagnosis (62%). Among the dementia cases, the median duration of observation time was
14 years.
Conclusion
We have created a generalisable, national dementia e-cohort, aimed at facilitating epidemiological
dementia research.
Introduction
Dementia is a major global health challenge [1,2] and the cur-
rent lack of disease-modifying therapies places the onus on
the research community to identify potentially modifiable risk
factors [3], as well as to study its incidence, prevalence and
natural history. The pathologies underlying neurodegenerative
diseases such as Alzheimer’s disease are likely to begin many
years before symptom onset [4], and so long follow-up times
are required to determine whether an association between a
given factor and dementia is truly causal or due to reverse
causation [5,6]. Longitudinal studies, with prospective data
collection, are therefore of great importance to improving our
understanding of dementia.
Dementias Platform UK (DPUK, www.dementiasplatform.
uk) is a UK-wide, public-private partnership, that aims to fa-
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cilitate and accelerate dementia research by providing a single
point of access to data for >2 million participants across >38
existing cohort studies. Many of these cohorts have provided,
and will continue to provide, important insights in the field
of dementia. However, as these cohorts require participant
consent for recruitment, they are likely to suffer from selection
bias [7–9]. In contrast, a nationwide cohort based on whole-
population administrative data is likely to avoid this issue, as
analyses based on it can be more readily generalised to other
populations.
The Secure Anonymised Information Linkage (SAIL) Data-
bank (https://saildatabank.com) is a remotely-accessible,
privacy-protecting data safe haven containing anonymised,
individual-level, linked routinely-collected health and social
care datasets for the population of Wales, UK [10–12]. Wales,
with a population of approximately three million people, is one
of four countries in the UK. A key enabler of data creation is
Wales’ National Health Service (NHS), which acts a single
provider of healthcare, free at the point of use to the res-
ident population. As a result, SAIL is a large, nationwide,
population-based research resource comprising longitudinal,
routinely-collected healthcare data. Its size, national coverage
and richness of available data means SAIL has the potential to
be of great value for dementia research [13]. However, it can
be a demanding task for researchers to transform the complex
and varied datasets into a study population appropriate for
their research question, as well as to identify participants with
dementia with a minimum of misclassification.
By applying coding algorithms to linked routinely-collected
datasets, we developed a novel DPUK cohort – the SAIL De-
mentia e-Cohort (SAIL-DeC). SAIL-Dec is a population-based
electronic cohort (e-cohort) containing health-related informa-
tion on people with and without diagnosed dementia. We de-
veloped SAIL-DeC to maximise its generalisability and utility
for a broad range of research questions and methodologies. For
example, we anticipate SAIL-DeC data being used to conduct
risk factor studies, explore geographical variations in demen-
tia incidence or outcomes, develop or validate risk prediction
models and perform health economic analyses.
We created SAIL-DeC with the aims of minimising dupli-
cation of effort, increasing reproducibility, reducing costs and




We have followed the Reporting of studies Conducted using
Observational Routinely-collected Data (RECORD) guideline
in formatting this manuscript [14]. The SQL script used
to create the cohort and cohort meta-data are available at
https://datashare.is.ed.ac.uk/handle/10283/3268.
SAIL Databank
The SAIL Databank, based at Swansea University, was de-
veloped based on four principles: (1) to operate a remote
access system, providing secure access to data to approved
researchers; (2) to provide a powerful data analytic platform;
(3) to ensure a robust mechanism for the safe transfer of ap-
proved files in and out of the system; and (4) to be efficient
and scalable [11].
SAIL uses a split-file anonymisation method to main-
tain confidentiality. Individuals within each routinely-collected
dataset are assigned a unique identifier (Anonymised Linking
Field [ALF]). The ALF is generated by NHS Wales Information
Service, a trusted third party, using the Matching Algorithm
for Consistent Results in Anonymised Linkage, which has an
accuracy of 99.85% [12,13]. Within SAIL, the ALF is fur-
ther encrypted (ALF-E) and used to link the now de-identified
individuals across multiple routinely-collected datasets, with
further encryption (ALF_PE) then applied before data are al-
located to an approved project.
Datasets
To construct SAIL-DeC, we used linked primary care, hos-
pital admissions, mortality and deprivation datasets (https:
//saildatabank.com/saildata/sail-datasets). Hospi-
tal admissions data (Patient Episode Database for Wales
[PEDW]), first collected in Wales in April 1991, contain in-
formation regarding inpatient admissions (emergency, elective
and maternity) and day-case procedures. Diagnoses within
PEDW are coded using the International Classification of Dis-
eases version 10 (ICD-10) system [15]. Mortality data (Annual
District Death Extract [ADDE]), available in SAIL since 1995
and derived from England and Wales’ death certification and
registration system, contain diagnoses of cause of death as
well as contributory comorbidities. ADDE uses ICD-9 coding
until 2001 [16], and ICD-10 coding thereafter. Primary care
data (Welsh Longitudinal General Practice dataset [WLGP]),
currently use the Read version 2 system [17,18], although this
will ultimately be replaced with the international SNOMED CT
system in the future [19]. While ICD-10 codes contain only
diagnostic information, Read codes contain information on di-
agnoses, administrative procedures, prescriptions, and symp-
toms and signs, making them a potentially rich resource for
a wide range of research. Currently, SAIL contains primary
care data for approximately 80% of the Welsh population.
The subpopulation for whom primary care data are available
are representative of the entire Welsh population in terms of
age, sex and deprivation (Supplementary Appendix 1). The
period of time covered by primary care data varies consider-
ably between individuals and across practices – we included all
available primary care data for all eligible participants. Depri-
vation data were derived from the Welsh Demographic Service
Dataset (WDSD). Within WDSD, the Welsh Index of Multiple
Deprivation [WIMD], is used to measure relative deprivation
based on geographical household location, for small areas in
Wales (Lower-layer Super Output Areas [LSOAs])[20]. To cre-
ate SAIL-DeC we used the 2011 version of WIMD, linked to
the 2001 version of LSOAs. In future updates of the cohort
we will be able to update these deprivation datasets as new
versions become available.
Study population
We included all participants within the SAIL Databank for
whom primary care data were available, based on being reg-
istered with a SAIL-contributing general practice (GP) at any
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point. We excluded participants with a date of birth listed as
before 1st January 1900, as we deemed these to be likely to
be incorrect. We also excluded participants whose 60th birth-
day would fall after the latest date of follow-up, because the
prevalence of dementia is very low below this age [21]. We
therefore included participants born between 1st January 1900
and 1st January 1958 in the initial cohort development. The
later date will change as the SAIL Databank receives updates
of the datasets in the future, meaning the cohort will continue
to increase in size over time as more participants become eli-
gible. The timing of cohort refreshes will be negotiated with
prospective applicants and available updates added to relevant
extracts within SAIL-DeC.
We defined the entry date into the cohort as the first date
of registration with a SAIL GP. We excluded participants with-
out a valid GP registration date. We defined the last date of
follow-up as the earliest of GP de-registration or death (cur-
rently January 2018).
Cohort tables
Using information from the four datasets, we created three
types of table (Figure 1):
1. A demographics table, with one row per participant.
This table holds basic demographic information and in-
formation on the follow-up time to allow survival analysis
and/or efficient case-control matching. This table also
contains information on the death date if appropriate
and indicator flags on whether the participant developed
all-cause dementia during follow-up. There is also a flag
for whether the participant received a dementia subtype
code.
2. A dementia events table, with multiple rows per partic-
ipant. This contains the code details, date and source
(i.e. primary care, hospital admissions or mortality data)
of each dementia code and the dementia subtype to
which the code refers.
3. Multiple risk factor/comorbidities events tables, with
multiple rows per participant. Using the same format
as the dementia events table, these tables contain infor-
mation on the specific code, date and data source for
each derived risk factor or comorbidity.
We created a data dictionary, which lists all cohort tables
and outlines the source of the derived variables for each table
type (Supplementary Appendix 2).
Derived variables
Dementia
We used a validated list of ICD-9, ICD-10 and Read V2 codes
to identify all-cause dementia, Alzheimer’s disease, vascular
dementia cases, dementia with Lewy Bodies and frontotempo-
ral dementia in primary care, hospital admissions or mortality
data (Supplementary Appendix 3). We developed the code
list based on findings from a systematic review of the accu-
racy of dementia coding in routinely-collected healthcare data
[22] and a UK-based validation study in which cases identified
from coded data were compared to the full-text medical record
[23]. We defined the date of diagnosis in the demographics
table as the date of the first all-cause dementia code in any
dataset. Where a participant had a dementia subtype code
(e.g. Alzheimer’s disease), we defined date of diagnosis as
the first date of any (all-cause) dementia code. Subtype code
categories were not mutually exclusive, so a participant with
≥ 1 Alzheimer’s disease and vascular dementia codes in any
dataset would be categorised as having both of these subtype
diagnoses.
Risk factors and comorbidities
We created ICD-9, ICD-10 and Read V2 code lists to derive
variables for risk factors and comorbidities based on a four-
stage process: (1) code lists used by existing studies [24–34];
(2) an online clinical codes repository [35]; (3) where avail-
able, the recommended Read code lists from the UK Quality
Outcomes Framework (QOF) [36] and (4) a manual review
of the codes by a clinician (TW) (Supplementary Appendices
4-6). Where possible, we used validated code lists with known
accuracy versus a definable reference standard; however, this
was not possible for the majority of variables. Researchers who
apply to use data from SAIL-DeC can use these code lists, or
create their own using the underlying datasets, thereby creat-
ing an iterative process in which we use feedback from users
of SAIL-DeC to improve and create different versions of the
definitions of derived variables over time.
Bias
As the SAIL Databank contains data for the entirety of Wales,
and primary care data for 80% of the population, we have at-
tempted to minimise selection bias by including all eligible
participants. We created code lists for diagnoses with the
intention of maximising positive predictive value (PPV, the
proportion of identified cases that are true cases) whilst main-
taining a reasonable sensitivity (the proportion of true disease
cases identified), in order to minimise bias in effect estimates
[37].
Statistical methods
We calculated the total number of people and number of
person-years of follow-up, stratified by sex, deprivation and
birth decade for the whole cohort and for the dementia cases.
For the dementia cases, we counted the number of partici-
pants who had a specific dementia subtype code (Alzheimer’s
disease, vascular dementia, dementia with Lewy Bodies and
frontotemporal dementia). We calculated the median dura-
tion of follow-up for the dementia cases, as well as the num-
ber of cases and follow-up time for dementia cases in whom
follow-up began prior to age 60. We also created an event
flow diagram, indicating to what extent and in which order
dementia cases were identified across multiple datasets. We
calculated the number of dementia cases and person-years at
risk for each derived risk factor or comorbidity.
Data access and cleaning methods
To create SAIL-DeC, we accessed all hospital admissions, mor-
tality, primary care and deprivation data contained within
SAIL. For the purposes of data cleaning, we excluded:
3
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Figure 1: Format of SAIL dementia e-cohort
Event tables consist of derived variables for: ever-smoking; obesity; hypertension; atrial fibrillation; peripheral arterial disease;
myocardial infarction; stroke; diabetes; asthma; cancer; chronic obstructive pulmonary disease; depression; epilepsy; heart failure;
hypothyroidism; osteoporosis; alcohol dependence; substance misuse; motor neurone disease; Parkinson’s disease; and rheumatoid
arthritis.
*field blank if participant did not develop dementia.
†Flag indicating that linkage to ≥ 1 datasets for this participant may not be accurate (<95% probabilistic matching).
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• Participants with a recorded date of birth before
1/1/1900;
• Any information from mortality data when the date of
death was recorded as being before 1/1/1980 or after
1/1/2020. Where a record in mortality data was miss-
ing but death was recorded in the WDSD dataset, we
used the latter to obtain the death date (7% of deceased
participants);
• Participants without a GP registration start or end date;
• Participants who had a dementia diagnosis without a
valid date (i.e. before 1/1/1900 or after 1/1/2018), as
we did not know whether they represented true cases.
SAIL contains information on the linkage quality of ALFs
obtained following deterministic and probabilistic matching
which have been through a standard split file approach. We
did not exclude participants based on low ALF matching rates,
but instead created a flag in the demographics table to indi-
cate where a participant has one or more linkages with <95%
probabilistic matching. Users of SAIL-DeC can therefore opt
to exclude participants of lower linkage quality depending on
their study requirements.
Results
Demographics of whole cohort and dementia
cases
From the 4,389,213 people within the SAIL Databank with
primary care data, 1,246,557 participants met the cohort in-
clusion criteria (Figure 2), resulting in 18,802,369 person-years
of follow-up. For the whole cohort, the median first GP regis-
tration date was October 1995, with a median age at registra-
tion of 59 years. For participants with a diagnosis of dementia,
the median date of first GP registration was January 1996 and
median age at registration was 71 years. The demographics of
the whole cohort and the dementia cases are displayed in Table




Of all SAIL-DeC participants, 129,650 (10%) developed all-
cause dementia during follow-up. Of these, 77,978 (60%) had
≥ 1 codes for a dementia subtype (Figure 3). Alzheimer’s dis-
ease was the most common subtype diagnosis (48,172, 62%),
followed by vascular dementia (36,949, 47%). 8,653 (11%)
participants with dementia had both Alzheimer’s disease and
vascular dementia codes.
Case ascertainment across datasets
From the 129,650 dementia cases, 78,828 (61%) were iden-
tified at any time in primary care data, 101,654 (78%) in
hospital admissions data and 52,198 (40%) in mortality data.
Forty-eight percent of participants were first identified in pri-
mary care data, 48% in hospital admissions data and 4% were
identified only in mortality data (Supplementary Appendix 7).
The number of dementia cases identified by each code are
summarised in Supplementary Appendix 8.
Observation period
Among dementia cases, the median duration of follow-up was
14 years. We were able to follow up 23,724 (18%) dementia
cases from <age 60 years, with a median follow-up time of
22 years. Seventy-nine percent of participants who developed
dementia died during follow-up.
Risk factors and comorbidities
The number of participants and duration of follow-up for
each risk factor or comorbidity among the 129,650 demen-
tia cases is displayed in Table 2. A detailed breakdown of
the number of participants identified by individual codes, as
well as the extent to which participants with each risk fac-
tor or comorbidity are identified in the datasets over time, is
available in Supplementary Appendices 9-29 and at https:
//datashare.is.ed.ac.uk/handle/10283/3268.
Discussion
We have applied algorithms to routinely-collected primary
care, hospital admissions, mortality and deprivation datasets
within the SAIL Databank to create a ‘real world’ demen-
tia e-cohort. We have incorporated this cohort into DPUK,
to complement existing, ‘consented’ cohort studies within the
initiative.
Flexibility
SAIL-DeC is designed to be flexible, meaning researchers can
choose to use the existing disease definitions or create new
ones to suit their purposes. For example, we used a validated
code list for dementia outcomes in which the presence of a sin-
gle dementia code in any dataset leads to a participant being
identified as a dementia case, with the date of the first de-
mentia code used to determine the ‘date of diagnosis’. Users
may wish to use an alternative definition of dementia – for
example, requiring >1 dementia codes in any data source, or
including prescriptions for dementia drugs (e.g., cholinesterase
inhibitors) in the algorithm. Similarly, they may wish to cre-
ate new comorbidity variables or adapt the existing ones. We
included all available data for all eligible participants, allowing
users of SAIL-DeC to create a sub-cohort relevant to their re-
search question. Researchers who intend to use SAIL-DeC as
a cohort study (e.g. when conducting a case-cohort analysis)
will need to select a time point from which follow up starts for
an individual, such as a specific date or participant age.
Identifying dementia cases using routinely-
collected healthcare data
For routinely-collected healthcare datasets to be used to iden-
tify dementia cases for research, they must do so with sufficient
accuracy [22]. If using the data for analyses of risk factors or
the natural history of dementia, identifying disease outcomes
with a high PPV is important in order to minimise the risk of
5
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Figure 2: Study flow diagram
*Currently April 2016
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Figure 3: Dementia subtypes
AD – Alzheimer’s disease, VaD – vascular dementia, DLB – dementia with Lewy Bodies, FTD – frontotemporal dementia, None
– no subtype code. Categories not mutually exclusive (apart from ‘none’ category). 77,978/129,650 (60.1%) of participants with
all-cause dementia had at least one dementia subtype code. 8653 participants had both Alzheimer’s disease and vascular dementia
codes (‘mixed dementia’).
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Table 1: Demographics of dementia cases and whole cohort
Whole cohort Dementia cases
n (%) Person-years n (%) Person-years
Total participants 1,246,557 18,796,117 129,650 1,773,462
Sex
Female 658,518 (53) 9,963,822 82,571 (64) 1,118,479
Male 588,035 (47) 8,832,289 47,079 (36) 654,983
Missing <5 (0) 5 0 (0) 0
Deprivation quintile*
1 (Most deprived) 224,376 (18) 3,276,397 24,915 (19) 334,806
2 238,021 (19) 3,438,409 26,344 (20) 353,203
3 264,799 (21) 3,939,140 27,798 (21) 377,314
4 242,115 (19) 3,696,385 25,317 (20) 346,736
5 (Least deprived) 255,363 (20) 4,223,548 24,033 (19) 350,798
Missing 21,883 (2) 222,238 1,243 (1) 10,604
Birth Decade
1900-1910 40,380 (3) 231,761 7,633 (6) 51,713
1911-1920 130,388 (10) 1,157,531 32,515 (25) 334,063
1921-1930 228,475 (18) 2,962,413 50,179 (39) 720,464
1931-1940 271,791 (22) 4,451,912 27,922 (22) 470,036
1941-1950 373,971 (30) 6,500,674 9,450 (7) 163,509
1951-1960 201,552 (16) 3,491,826 1,951 (2) 33,677
*Latest deprivation score for each participant
bias (37). Validation studies of UK routinely-collected health-
care data to identify dementia cases have reported PPVs of
83-100% [23,38,39], 85-87% [23,40] and 80-90% [23,41] for
primary care, hospital admissions and mortality data respec-
tively.
The sensitivity (the proportion of true disease cases iden-
tified) of using routinely-collected healthcare data to identify
disease outcomes is another important consideration. There
is a trade-off between PPV and sensitivity, meaning case as-
certainment methods with a high PPV may fail to identify a
proportion of ‘true’ cases. Studies of the sensitivity of hospi-
tal admissions and mortality data in patients known to mental
health services with dementia (and therefore likely to overes-
timate sensitivity as it does not account for the proportion
of people with dementia who are undiagnosed) reported esti-
mates of 78% and 54% respectively [42,43]. The sensitivity
of UK primary care data is currently unknown [22], although
a study is underway to investigate this [44].
The use of multiple data sources improves our understand-
ing of the timing of a dementia diagnosis, as in some cases
there can be a significant delay between the identification of a
participant with dementia in one dataset compared to others
(Supplementary Appendix 7). This is particularly important
for analyses in which the date of dementia diagnosis is needed,
such as time-to-event analyses.
Potential uses
There are numerous potential uses for this cohort. Given the
breadth of primary care Read codes, there is the opportunity
to identify novel risk factors for dementia and its subtypes.
For example, there is increasing evidence that some drugs are
associated with an increased risk of dementia [45–47]. The pri-
mary care dataset within SAIL-DeC contains details of all drug
prescriptions, meaning the cohort could be used to explore this
issue. Recent work by the Whitehall II study has shown the
importance of long follow-up times to explore whether associ-
ations between various factors and dementia are in fact due to
the effects of dementia on the factor itself (reverse causation)
[5,6]. The long follow-up times in SAIL-DeC would enable
such studies for a variety of risk factors.
Routinely-collected healthcare datasets have been used to
study dementia incidence and prevalence [48,49], as well as to
investigate within-country geographical variations in dementia
outcomes [50]. As SAIL have obtained primary care data for
a large proportion of the Welsh population, with included par-
ticipants representative of the wider population, the dataset
provides an opportunity to explore geographical variations in
dementia incidence or outcomes.
Of the participants who developed dementia, 79% died
during follow-up. This shows that, for many participants,
follow-up until death was ‘completed’ (i.e. not censored early).
SAIL-DeC would therefore be well suited to studies surround-
ing end of life for people diagnosed with dementia.
Primary care data have been used to develop and validate
risk prediction models for a range of diseases [51–53]. Given
that the variables within SAIL-DeC are all routinely-collected,
any variables used in a dementia risk prediction model devel-
oped using the cohort’s data would be applicable to current
clinical use.
8
Wilkinson, T et. al. / International Journal of Population Data Science (2020) 5:1:07
Table 2: Numbers and person-years of follow-up for risk factors or comorbidities across 129,650 dementia cases
Risk factor / comorbidity Dementia cases
n (%) Person-years
Ever-smoker 67,775 (52) 1,070,030
Obesity 9,197 (7) 161,496
Hypertension 81,377 (63) 1,211,400
Diabetes mellitus 29,745 (23) 430,198
Osteoporosis 24,486 (19) 381,686
Atrial fibrillation 38,866 (30) 556,328
Myocardial infarction 22,194 (17) 310,403
Heart failure 31,703 (24) 426,072
Peripheral arterial disease 9,612 (7) 136,934
Stroke 32,240 (25) 427,974
Depression 39,130 (30) 587,340
Parkinson’s disease 9,845 (8) 128,771
Epilepsy 9,496 (7) 128,487
Motor neurone disease 332 (0) 4,284
Asthma 22,303 (17) 338,197
Chronic obstructive pulmonary disease 24,444 (19) 346,059
Cancer 34,663 (27) 496,564
Rheumatoid arthritis 5,597 (4) 82,091
Hypothyroidism 18,663 (14) 273,953
Alcohol dependence 6,289 (5) 89,684
Substance misuse 2,323 (2) 36,589
Chronic kidney disease* 26,821 (21) 447,895
*Chronic kidney disease stages III-V. ICD-9, ICD-10 and Read V2 codes used to derive the variables are displayed in Supplementary
Appendices 4-6. A detailed breakdown of the number of participants identified by each individual code is available in Supplementary
Appendices 9-29 and at https://datashare.is.ed.ac.uk/handle/10283/3268.
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The breadth of information contained within Read codes
raises the possibility of using data within the cohort for
hypothesis-free studies of dementia, such as environment-wide
association studies [54,55]. With >100,000 dementia out-
comes within SAIL-Dec, the cohort is likely to provide suf-
ficient statistical power for such analyses.
In addition to hospital admissions data, SAIL also contains
other healthcare datasets such as emergency attendances, crit-
ical care admissions, care home residence, pathology results
and outpatient referrals. Other routine datasets are continuing
to be linked to SAIL participants, and these could be linked to
SAIL-DeC participants when they are made available. These
datasets may provide a useful means with which to conduct
health economic analyses for dementia care. There are also
plans to derive new phenotype data from multiple sources of
NHS clinical data using natural language processing, such as
radiology reports and free-text correspondence between clini-
cians.
Accessing the data
Researchers interested in using SAIL-DeC data can con-
tact the SAIL Databank directly (https://saildatabank.
com/application-process), or approach DPUK via the
DPUK portal (https://portal.dementiasplatform.uk),
who can facilitate the application. Applicants must submit
their proposal to the independent Information Governance Re-
view Panel (IGRP), which ensures proper and appropriate use
of SAIL data. Researchers are required to demonstrate appro-
priate Information Governance training prior to being provided
with remote access to the SAIL safe haven [11]. Costs depend
on the complexity of the project and support required and are
outlined early in the project scoping process. Our intention is
that using the pre-prepared SAIL-DeC datasets should reduce
the complexity of data preparation, thereby minimising costs
and time needed for new studies.
Strengths and limitations
SAIL-DeC has several strengths as a research resource. It
is population-based, and contains data for ∼80% of Wales,
meaning that it is likely to be generalisable to other similar
populations and should not suffer from the ‘healthy cohort
effect’ [7–9]. This is reflected in the near-equal distribution
of participants across deprivation quintiles. Its size is another
strength. With 18.8 million person-years of follow-up in the
whole cohort, there is likely to be sufficient power for most
types of analyses, even on relatively rare exposures or out-
comes. In creating the e-cohort, we have attempted to make
it useful for a wide range of research studies, with the aim of
increasing efficiency and reducing costs for researchers. We
have used coded algorithms to simplify the routinely-collected
datasets, with the intention of enabling researchers without ex-
perience of using UK healthcare datasets to use SAIL data. We
have created derived variables for many comorbidities and risk
factors, but the resource is designed to be flexible: users can
request additional variables or alter how variables are defined
if required for their analyses. Furthermore, if users change
how some derived variables are defined (i.e. codes removed or
added, or more complex algorithms created) based on their ex-
perience or the latest evidence, we can alter the definitions of
these variables for other researchers too, creating a ‘learning’
resource for the dementia research community.
The e-cohort also has several limitations. First, routinely-
collected healthcare data will not identify dementia cases with
perfect accuracy. Whereas validation studies have shown PPV
to be generally high across UK datasets, no studies have calcu-
lated the sensitivity of using primary care, hospital admissions
and mortality data in combination [22]. To have the opportu-
nity to appear in routinely-collected data, people with demen-
tia must first be known to healthcare services with a dementia
diagnosis, and dementia is known to be underdiagnosed [56],
meaning sensitivity is likely to be lower than PPV. This means
that SAIL-DeC would probably not be an appropriate resource
with which to calculate absolute dementia prevalence and in-
cidence in Wales as it will likely underestimate the number
of cases. However, it could be used to compare the relative
burden of dementia across different geographical areas.
The accuracy of the algorithms used to derive many of the
variables for risk factors and comorbidities is not known. We
have attempted to use algorithms with a presumed high PPV
over sensitivity, by including codes we consider likely to reflect
true positive cases and excluding codes that may introduce
false positive cases. This means that some of our algorithms
may identify risk factors and comorbidities with a low sensitiv-
ity, as suggested by the low rates of obesity (7%) at any point
for the dementia cases. It is likely that some of the factors,
particularly those for which recording is mandatory in QOF,
are better recorded and therefore more likely to be detected
than others. Our intention is that this will improve over time:
as new validation studies of these variables are performed, and
users of SAIL-DeC provide feedback on the code lists for these
variables, we will update these algorithms to maximise their
accuracy. For example, there is the potential to create more
complex algorithms (e.g. by including continuous measure-
ments such as body mass index for obesity or blood pressure
readings for hypertension), to improve case ascertainment for
some variables.
Although UK routinely-collected healthcare datasets iden-
tify all-cause dementia cases with a high PPV, the PPVs for
the identification of dementia subtypes is lower. Using UK
hospital admissions, mortality and primary care data in com-
bination, PPVs were estimated as 71% for Alzheimer’s disease
and 44% for vascular dementia [23]. There have been no
validation studies estimating the PPVs for rare dementia sub-
types such as dementia with Lewy Bodies and frontotemporal
dementia [22]. Researchers should consider this when using
SAIL-DeC to study dementia subtypes rather than all-cause
dementia.
Furthermore, SAIL-DeC relies entirely on routinely-
collected data to identify dementia cases as well as risk factors
and other comorbidities. Although Read coding in primary
care data provides a wide range of information in addition to
diagnoses such as symptoms, signs, administrative procedures
and prescriptions, there is limited phenotypic depth – for ex-
ample there is no imaging, free-text or genetic data. Over
time this may change, as SAIL obtains linkage to more de-
tailed datasets.
The availability of primary care data in SAIL increased over
time, as practices switched to electronic records, meaning the
primary care records further back in time are less complete.
We therefore have less information on participants earlier in
10
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life compared to later life, which may limit the use of cohort
to study early or midlife risk factors for dementia. The intro-
duction of QOF from 2004 onwards changed the way in which
GPs were remunerated, and this led to changes in how GPs
coded diagnoses and symptoms for certain conditions [57,58].
Dementia was introduced to QOF in 2006/2007, resulting in
a sudden increase in dementia primary care codes around this
time. Researchers using SAIL-DeC for survival analyses may
wish to consider this when selecting their study time window.
Conclusion
In conclusion, we have applied coding algorithms to primary
care, hospital admissions and mortality data to create SAIL-
DeC, a national dementia e-cohort, to complement existing
cohorts within DPUK. The cohort will enable researchers to
conduct a wide range of analyses related to dementia, whilst
minimising duplication of effort, time and cost.
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